Premium Nahrungsergänzungsmittel | artgerecht

Erythropoietin Deficiency – Causes, Symptoms & Treatment

Erythropoietin deficiency occurs when the kidneys produce insufficient EPO, the hormone that stimulates red blood cell production, often leading to anemia in chronic kidney disease.

Regular tips about health Regular tips about health

Things worth knowing about "Erythropoietin Deficiency"

Erythropoietin deficiency occurs when the kidneys produce insufficient EPO, the hormone that stimulates red blood cell production, often leading to anemia in chronic kidney disease.

What is Erythropoietin Deficiency?

Erythropoietin (EPO) is a hormone produced mainly by the kidneys that stimulates the bone marrow to produce red blood cells (erythrocytes). Erythropoietin deficiency occurs when the kidneys fail to produce adequate amounts of EPO, resulting in insufficient red blood cell production. This leads to a condition known as renal anemia – a form of anemia directly associated with reduced kidney function.

Causes

The most common cause of erythropoietin deficiency is chronic kidney disease (CKD). Other contributing causes include:

Chronic kidney insufficiency: Damaged kidney tissue produces less EPO.
Dialysis dependency: Patients on dialysis are particularly prone to EPO deficiency.
Congenital disorders (rare): In very rare cases, an inherited defect in EPO production may be present.
Severe systemic diseases: Certain chronic inflammatory conditions, malignancies, or severely impaired liver function can reduce EPO synthesis.
Medication effects: Certain drugs can inhibit EPO production.

Symptoms

Since erythropoietin deficiency leads to anemia, symptoms are typical of low red blood cell levels:

Fatigue and exhaustion
Pale skin and mucous membranes
Shortness of breath and reduced physical capacity
Heart palpitations
Difficulty concentrating and headaches
Dizziness

In advanced anemia, the heart may become strained, potentially increasing the long-term risk of cardiovascular complications.

Diagnosis

Diagnosis of erythropoietin deficiency involves a combination of clinical assessment and laboratory tests:

Complete blood count (CBC): Measurement of hemoglobin, hematocrit, and red blood cell count to identify anemia.
Serum EPO level: Measurement of erythropoietin concentration in the blood; in renal anemia, EPO levels are inappropriately low despite anemia.
Kidney function markers: Creatinine, urea, and estimated glomerular filtration rate (eGFR) indicate the degree of kidney impairment.
Iron studies: Ferritin, transferrin saturation, and related parameters, as iron deficiency can worsen anemia.

Treatment

Erythropoiesis-Stimulating Agents (ESAs)

The primary treatment is the administration of erythropoiesis-stimulating agents (ESAs), which are synthetic EPO preparations. These are typically given by subcutaneous injection or intravenously. Commonly used agents include epoetin alfa, epoetin beta, darbepoetin alfa, and newer formulations such as methoxy polyethylene glycol-epoetin beta.

Iron Supplementation

Adequate iron is essential for red blood cell production. Many patients also receive iron therapy, often intravenously, to maximize the effectiveness of ESA treatment.

HIF Prolyl-Hydroxylase Inhibitors (HIF-PHI)

Newer oral agents known as HIF prolyl-hydroxylase inhibitors (e.g., roxadustat, daprodustat) stimulate the body to increase its own EPO production and represent an additional treatment option.

Treatment of the Underlying Condition

Whenever possible, addressing the underlying kidney disease or other contributing causes is important to support EPO production or at least slow disease progression.

References

Kidney Disease: Improving Global Outcomes (KDIGO) – KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease (2012, updated 2024). Available at: https://kdigo.org
Eschbach JW, Egrie JC, Downing MR et al. – Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. New England Journal of Medicine, 1987; 316(2):73-78.
Pfeffer MA, Burdmann EA, Chen CY et al. – A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. New England Journal of Medicine, 2009; 361(21):2019-2032.

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.